logo

EVA Pharma Signs an Agreement with Batterjee to Localize the Manufacturing of Mental Health Therapies in Saudi Arabia.

15 Dec, 2025
https://evawebsite.blob.core.windows.net/strapi-v5/assets/Whats_App_Image_2025_12_25_at_11_19_14_AM_optimized_900_0996bc048f.jpeg

EVA Pharma Signs an Agreement with Batterjee to Localize the Manufacturing of Mental Health Therapies in Saudi Arabia.

15 Dec, 2025

Riyadh, Kingdom of Saudi Arabia, December 16, 2025: 

During its participation in the "Saudi Made" exhibition, EVA Pharma announced the signing of a new cooperation agreement with “Batterjee Pharma”. The agreement aims to localize the technology for manufacturing mental health therapies inside the Kingdom of Saudi Arabia. This step supports the Kingdom's vision toward achieving pharmaceutical security. 

This agreement is to establish EVA Pharma’s presence in the Saudi market. It also translates the company's commitment to supporting Saudi Vision 2030, which places the localization of advanced pharmaceutical industries at the top of its priorities in the healthcare sector. 

This cooperation with "Batterjee" reflects EVA Pharma’s regional strategy, which aims to transfer and localize vital pharmaceutical technologies. Producing mental health treatment locally, according to the highest quality standards, contributes to strengthening the company’s role as an active partner in developing the healthcare system in the Kingdom. 

-End- 

 
About EVA Pharma  

EVA Pharma industry is a subsidiary of EVA Pharma Holding, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma Industry is a local pharmaceutical manufacturer registered in Saudi Arabia, with a focus on sustainability and local investment in the Kingdom. 
 
EVA Pharma is committed to improving access to high-quality medicines at an affordable price worldwide, focusing on 3 main pillars: Innovation, Development, and Sustainable Access. The company utilizes the latest technologies in two research centers, offering capabilities that are the first of their kind in the Middle East and Africa. This includes research and development in messenger RNA (mRNA), ranging from AI-based predictions to biological products. 

A team of 5,000 professionals works at EVA Pharma. The company produces over one million healthcare products daily in four state-of-the-art manufacturing facilities. These facilities are internationally recognized for innovation and hold approvals from multiple regulatory authorities. 

Led by a relentless drive to ensure sustainable access to urgent disease areas that have not yet been met, the company’s products focus on 12 therapeutic areas: Anti-infectives, Metabolic health, Orthopedics, Neuroscience, Oncology, Respiratory, Gynecology, Urology and Andrology, Pediatrics, Ophthalmology, Gastroenterology, and Family medicine. These cover both local and international demand. 

For more information about the company, please visit  https://www.evapharma.com/en-SA and https://www.evapharma.com/newsroom, or follow us on: X, LinkedIn, Instagram.  

eva logo

We empower the fight for health and well being as a human right.

Subscribe for our latest news and updates

For adverse events reporting, please contact us on

PV.Report@evapharma.com

This content is exclusively designed for healthcare professionals based in Saudi Arabia

© 2026 Eva Pharma All Rights Reserved